Consistently Reproducible Fixed Drug-induced Urticaria in a Patient with Metastatic Melanoma Under Immunotherapy

Esen BH, Özbek L, Oğuz S, Selçukbiricik F. Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: a comprehensive analysis of FDA adverse event reporting system (FAERS) database. Heliyon 2024; 10: e33765.

https://doi.org/10.1016/j.heliyon.2024.e33765 DOI: https://doi.org/10.1016/j.heliyon.2024.e33765

Eshaq AM, Flanagan TW, Ba Abbad AA, Makarem ZAA, Bokir MS, Alasheq AK, et al. Immune checkpoint inhibitor--associated cutaneous adverse events: mechanisms of -occurrence. Int J Mol Sci 2024; 26: 88.

https://doi.org/10.3390/ijms26010088 DOI: https://doi.org/10.3390/ijms26010088

Mital R, Cartron AM, Trinidad JC, Spaccarelli N, Gibbons-Fideler IS, Kaffenberger BH, et al. Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy. JAAD Case Rep 2022; 31: 124-127.

https://doi.org/10.1016/j.jdcr.2022.11.020 DOI: https://doi.org/10.1016/j.jdcr.2022.11.020

Gultekin TTK, Emeksiz ZS, Selmanoğlu A, Misirlioglu ED. Nonsteroidal anti-inflammatory drug-induced fixed urticaria: first pediatric case report. Ann Allergy Asthma Immunol 2024; 133: 470–472.

https://doi.org/10.1016/j.anai.2024.06.030 DOI: https://doi.org/10.1016/j.anai.2024.06.030

Çelik HI, Akay E, Emeksiz ZŞ, Işık M, Yaralı HN, Mısırlıoğlu ED. Pediatric hemophilia patient: successful desensitization for drug-induced fixed urticaria with prothrombin complex concentrate. Pediatr Allergy Immunol 2024; 35: e14105.

https://doi.org/10.1111/pai.14105 DOI: https://doi.org/10.1111/pai.14105

Argiz L, Múgica MV, Vega F, Blanco C. Drug-induced fixed urticaria as a presentation of NSAID intolerance. J Allergy Clin Immunol Pract 2019; 7: 1306–1307.

https://doi.org/10.1016/j.jaip.2018.10.030 DOI: https://doi.org/10.1016/j.jaip.2018.10.030

Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Rodriguez-Rodriguez M, Antolin-Amerigo D, Vélez D, Medina-Exposito I, et al. Fixed drug urticaria: a report of two patients. Allergol Int 2015; 64: 101–103.

https://doi.org/10.1016/j.alit.2014.07.007 DOI: https://doi.org/10.1016/j.alit.2014.07.007

Uetsu N, Murata C, Okamoto H. Childhood fixed solar urticaria induced by visible light. Photodermatol Photoimmunol Photomed 2023; 39: 159–161.

https://doi.org/10.1111/phpp.12850 DOI: https://doi.org/10.1111/phpp.12850

Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9: 71–77.

https://doi.org/10.1007/s11882-009-0011-8 DOI: https://doi.org/10.1007/s11882-009-0011-8

Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002; 2: 317–323.

https://doi.org/10.1097/00130832-200208000-00005 DOI: https://doi.org/10.1097/00130832-200208000-00005